Safety Profile of CAP7.1 Obtained During Phase I Trial in Adult Patients with Refractory Malignancies

    P. Mehlitz
    Studysummary In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on refubium.fu-berlin.de →
    Discuss this study in the Community →